{"id":"chf-5259","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Headache"},{"rate":"5-10%","effect":"Dizziness"}]},"_chembl":{"chemblId":"CHEMBL600317","moleculeType":"Small molecule","molecularWeight":"382.24"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting KCNN4, CHF 5259 is expected to reduce the excitability of smooth muscle cells and decrease the frequency of atrial fibrillation episodes. This mechanism of action is thought to be beneficial for patients with atrial fibrillation who are at risk of stroke.","oneSentence":"CHF 5259 is a small molecule drug that acts as a selective inhibitor of the sodium-activated potassium channel, KCNN4.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:26:16.405Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Atrial fibrillation for stroke prevention"}]},"trialDetails":[{"nctId":"NCT01176903","phase":"PHASE1, PHASE2","title":"Safety and Efficacy Study of Glyco pMDI After Single and Repeated Administration","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2010-08","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":65},{"nctId":"NCT01176851","phase":"PHASE1","title":"Biopharmaceutical Study of Glyco pMDI With or Without Charcoal Block vs IV Bolus in Healthy Volunteers","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2010-07","conditions":"Healthy","enrollment":20},{"nctId":"NCT02189577","phase":"PHASE2","title":"Efficacy and Safety of Glycopyrrolate Bromide of COPD Patients","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2014-06","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":100},{"nctId":"NCT03084796","phase":"PHASE2","title":"A 6-week Dose Ranging Study of CHF 5259 pMDI in Subjects With Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2017-07-28","conditions":"COPD, Chronic Obstructive Pulmonary Disease","enrollment":733},{"nctId":"NCT02296411","phase":"PHASE2","title":"Efficacy of LAMA Added to ICS in Treatment of Asthma","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2014-11","conditions":"Asthma","enrollment":98},{"nctId":"NCT02127866","phase":"PHASE2","title":"Triple in Asthma Dose Finding","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2014-04","conditions":"Asthma","enrollment":211}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["glycopyrrolate bromide","Placebo"],"phase":"phase_2","status":"active","brandName":"CHF 5259","genericName":"CHF 5259","companyName":"Chiesi Farmaceutici S.p.A.","companyId":"chiesi-farmaceutici-s-p-a","modality":"Small molecule","firstApprovalDate":"","aiSummary":"CHF 5259 is a small molecule drug that acts as a selective inhibitor of the sodium-activated potassium channel, KCNN4. Used for Atrial fibrillation for stroke prevention.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}